Your browser doesn't support javascript.
loading
Emerging Applications and Regulatory Strategies for Advanced Medicines Manufacturing - Towards the Development of a Platform Approach.
Srai, Jagjit Singh; Bauer, Paul; Badman, Clive; Bresciani, Massimo; Cooney, Charles L; Florence, Alastair; Hausner, Doug; Konstantinov, Konstantin; Lee, Sau L; Mascia, Salvatore; Nasr, Moheb; Trout, Bernhardt L.
Afiliação
  • Srai JS; Department of Engineering, University of Cambridge, UK. Electronic address: jss46@cam.ac.uk.
  • Bauer P; Department of Engineering, University of Cambridge, UK.
  • Badman C; University of Strathclyde, UK.
  • Bresciani M; EPSRC Future Continuous Manufacturing and Advanced Crystallisation Hub (CMAC), University of Strathclyde, UK.
  • Cooney CL; Emeritus, Department of Chemical Engineering MIT, Cambridge MA, United States.
  • Florence A; EPSRC Future Continuous Manufacturing and Advanced Crystallisation Hub (CMAC), University of Strathclyde, UK.
  • Hausner D; Continuous Manufacturing, OSD, Pharma Services Group, Thermo Fisher Scientific, United States.
  • Konstantinov K; Ring Therapeutics, Cambridge, MA, United States.
  • Lee SL; Office of Pharmaceutical Quality/CDER/FDA, Silver Spring, United States.
  • Mascia S; CONTINUUS Pharmaceuticals, Woburn, MA, United States.
  • Nasr M; Nasr Pharma Regulatory Consulting (NPRC), United States.
  • Trout BL; Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, MIT, United States.
J Pharm Sci ; 113(7): 1701-1710, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38663498
ABSTRACT
The last decade has seen Advanced Medicines Manufacturing (AMM) progress from isolated product developments to the creation of industry-academic centres of excellence, regulatory innovation progressing leading to new standards, and product commercialisation across multiple product formats. This paper examines these developments focusing on successful applications and strategies presented at the 2023 Symposium of the International Consortium for Advanced Medicines Manufacturing (ICAMM). Despite these exemplar applications, there remain significant challenges to the sector-wide adoption of AMM technologies. Drawing on Symposium delegate expert responses to open-ended questions, our coding-based thematic analysis suggest three primary enablers drive successful adoption of AMM technologies at scale, namely the ability to leverage pre-competitive collaborations to challenge-based problem solving; information and knowledge sharing through centres of excellence; and the development of AMM specific regulatory standards. Further analysis of expert responses identified the emergence of a 'Platform creation' approach to AMM innovation; characterised by i) New collaboration modes; ii) Exploration of common product-process platforms for new dosage forms and therapy areas; iii) Development of modular equipment assets that enable scale-out, and offer more decentralized or distributed manufacturing models; iv) Standards based on product-process platform archetypes; v) Implementation strategies where platform-thinking and AMM technologies can significantly reduce timelines between discovery, approval and GMP readiness. We provide a definition of the Platform creation concept for AMM and discuss the requirements for its systematic development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tecnologia Farmacêutica / Indústria Farmacêutica Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tecnologia Farmacêutica / Indústria Farmacêutica Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article